Commercial Page
Tirzepatide GLP-1 / GIP Injections
Explore Embody's weekly tirzepatide path, including how the intake works, what provider review covers, and how the higher-intensity option is framed.
Adults comparing the stronger tirzepatide-led path and wanting a tighter view of program flow, support, and provider review before they begin.
This page is for visitors who already know they want the weekly GLP-1 / GIP route and need clearer expectations than a broad category page can provide.
Embody frames tirzepatide as the more advanced weekly GLP-1 / GIP option. This page exists to explain the commercial and process differences without blurring them into generic outcome claims.
- Complete the Embody intake and provide the information needed for the provider review
- A licensed provider evaluates whether a tirzepatide path is an appropriate next step
- If approved, prescription handling, ongoing support, and shipping move into the active treatment workflow
- Weekly dual-pathway option for visitors who already know they want the tirzepatide route
- Clearer separation from the semaglutide offer so intent stays specific
- Connects the product decision to provider review, support, and policy pages
- Approval, titration, and refill cadence remain with the treating provider and pharmacy workflow
- Higher-intensity treatment questions should be answered before the click, not after checkout
- This page should set expectations clearly without implying guaranteed access or guaranteed results
- Matches tirzepatide-specific intent instead of mixing all products together
- Links to trust, methodology, and policy pages before the visitor leaves the site
- Uses practical language around fit, program structure, and ongoing support expectations
How Embody Works
Understand Embody's intake, provider review, support model, and shipping flow before you choose between the semaglutide and tirzepatide paths.
Semaglutide vs Tirzepatide
A comparison hub for Embody's two featured weekly injection paths, built for visitors deciding between semaglutide and tirzepatide.
Cost, Support, and Eligibility
A hub page for self-pay expectations, provider approval questions, support details, and the trust information visitors want before choosing an Embody treatment path.
FAQs
Questions this page should answer before the CTA
Keep the next step tied to fit
Visitors should understand the referral model, the role of independent providers, and the relevant policy pages before they click through.
Prescription GLP-1 options require evaluation by a licensed provider. Eligibility, dosing, fulfillment, and ongoing treatment decisions depend on medical appropriateness, state-specific rules, and the provider review.